Living Fully Beyond Cancer: New Treatment Options and Woman to Woman Group Help Two-Time Cancer Survivor Find Strength and Connection

A photo of Victoria Rosen

Victoria Rosen visiting the Alcazar Gardens in Seville, Spain following her first bout with cervical cancer in 2023.

Victoria Rosen, 74, is a long-time New Yorker and two-time cervical cancer survivor with a positive outlook on life. She loves to travel and approaches her city like a tourist, exploring its parks, museums, libraries, and theaters. She is the friend who can be counted on to accept a last-minute invitation, whether it means catching a show or discovering something new.

Her curiosity and zest for life reflect a spirit that has carried her through two battles with cancer.

She also credits Woman to Woman at the Mount Sinai Tisch Cancer Center, which for more than 20 years has supported women with gynecologic cancer and empowered them to inspire others facing cancer. The program matches people in treatment or follow-up care with trained volunteers who have had gynecologic cancer.

“The journey back after cancer treatment can be challenging,” she said after attending the 29th Woman to Woman Biannual Reunion. “I see all that Woman to Woman does. It’s the small things that add up. They’re so thoughtful.” The event was held Saturday, November 14, at Saint Jean Baptiste School in Manhattan.

Ms. Rosen regularly attends the reunions and says she likes how each one has a unique theme that covers many helpful topics affecting women during, before and after cancer treatment.

The theme of the 29th reunion was “Strength Beyond Cancer” with a focus on lifestyle practices and practical ways to care for your body.

Ms. Rosen embodies that resilience and practical strength in her everyday life. She makes a point of staying active, spending time in nature, and remaining engaged with the world around her.

In 2023 she was diagnosed with advanced, stage IV cervical cancer, and underwent surgery to surgically remove as much of the cancerous tumor as possible. She also received chemoradiotherapy followed by four cycles of chemotherapy.

That was when she first started attending the Woman to Woman group events.

She then had a recurrence in October 2025. This time, thanks to advances in research, her doctors at the Mount Sinai Tisch Cancer Center presented new treatment options in the form of targeted immunotherapies.

What are immunotherapies?

Immunotherapies are a type of medical treatment that uses your body’s natural immune system to fight diseases such as cancer, allergies, and autoimmune conditions.

Using the latest screening technology, oncologists at Mount Sinai Tisch Cancer Center identified a specific protein called a biomarker.

The biomarker indicates that the tumor is actively using this protein to shield itself from your body’s defenses. This finding suggests the tumor may respond well to a type of immunotherapy called immune checkpoint inhibitors.

Her treatment combined an immunotherapy medication, Keytruda®, with two chemotherapy drugs,  carboplatin and paclitaxel, according to her oncologist, Theresa Shao, MD, Assistant Professor of Medicine ( Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.

Dr. Shao says Ms. Rosen has been doing well on this regimen with her most recent scan showing no evidence of recurrent disease.

“Her resilience through such a difficult journey is remarkable,” said Dr. Shao. “Even on the hardest days, she always does it with a smile.”

A photo of Victoria Rosen at a party.

“It’s the small things that add up. They’re so thoughtful,” Victoria Rosen says of Mount Sinai’s Woman to Woman support group. She is shown at a friend’s party in 2026.

Strength Beyond Cancer

Ms. Rosen recognizes the importance of having people to turn to when the challenges of cancer extend beyond medical treatment.

For example, w​ith the help of the Woman to Woman network, she was connected to mental health resources, and received eight free sessions with a trained therapist. The organization also provides wigs to women who have lost their hair during chemotherapy, along with free beauty kits.

Ms. Rosen represents the spirit of resilience that is critical to the mission of the Woman to Woman group at Mount Sinai.

“Victoria is a truly wonderful person. Her warmth, curiosity, and zest for life are inspiring, and the courage she has shown in facing a second battle with cancer is remarkable,” said Jilian Levinson, LCSW, OSW-C, who leads the program along with Rachel Justus, LCSW. “She reminds us that survivorship is about so much more than getting through treatment. It’s about continuing to live fully, finding joy, and staying connected to the people and experiences that give life meaning.”

The Woman to Woman reunion also featured physical therapists Mary Ellen Herdley, PT, and Alina Herdaya, DPT, PT, OCS, and occupational therapist Jennifer Hrdina who discussed fatigue, neuropathy, and wellness during treatment, recovery, and survivorship.

“The reunion is designed for the Woman to Woman community including patients, mentors, loved ones and caregivers, and is a great setting for connection, education and celebration,” said Ms. Levinson.

A Cancer Survivor’s Story: When She Was Diagnosed With Late-Stage Lung Cancer, Her Prognosis Was Poor. 13 Years Later, She Is Thriving and Fulfilling Her Dream to Raise a Family

Emily Bennett Taylor with her husband, Miles, and their children, Maggie, Brody, and Hope.

In June 2012, Emily Bennett Taylor, a former college volleyball player from Los Angeles, was preparing to celebrate her second wedding anniversary when she visited her primary care doctor after she developed a persistent dry cough and shortness of breath.

Her doctor thought it might be asthma, so he referred her to a pulmonologist for a chest X-ray. The pulmonologist assured her that because of her age and good health, lung cancer was unlikely.

Days later, a follow-up CT scan and biopsy confirmed she had cancer in her right lung that had spread to the surrounding lung lining. She was shocked. She had never smoked.

And at that time, just one percent of people diagnosed with stage IV non–small cell lung cancer lived five years or longer.

But at Mount Sinai, she found Raja Flores, MD,  a surgeon who would treat her when others said surgery could not rid her body of the cancer. Now she is raising the family she had once thought would be impossible.

“I truly believe that the surgery Dr. Flores performed on me when no one else would is what saved my life,” she says. “If we had followed what was then considered the standard of care for my diagnosis, I have no doubt that I would not be here to enjoy life with my family.”

For Dr. Flores and her Mount Sinai team, her journey is another reminder that there can be life after cancer.

Before finding Dr. Flores, Ms. Bennett Taylor began a combination regimen over six months that included chemotherapy drugs carboplatin, Alimta®, and Avastin®. But her doctors explained it was only a matter of time before the cancer would start growing again.

For months she was told there was little hope, and four surgeons said no because patients with stage IV lung cancer generally do not succeed in ridding the body of the disease. Then she found Dr. Flores, Chair of Thoracic Surgery at the Icahn School of Medicine at Mount Sinai.

Photo of Emily Bennett Taylor with her surgeon, Raja Flores, MD, in the ICU after surgery in 2013.

Emily Bennett Taylor with her surgeon, Raja Flores, MD, in the ICU after surgery in 2013.

He reassured her that because of her age and the fact that the cancer had not yet spread beyond the chest cavity, she was a candidate for surgery.

For months, Dr. Flores received her scans from her hospital in California. When it appeared the tumor was not spreading, he contacted her. “It’s time, we’re going to do it, now is when we do surgery,” he told her.

Ms. Bennett Taylor and her husband, Miles, booked a flight to New York City, arriving on January 30, 2013.

In early February, Dr. Flores did video-assisted thoracic surgery to confirm that the cancer was in the lung’s lining.

After confirmation, Dr. Flores performed an extrapleural pneumonectomy, a complex procedure that removed the patient’s right lung, the linings of the chest cavity and lung, and a portion of her diaphragm. She also had positive lymph nodes. He also removed and rebuilt the membrane surrounding her heart.

After surgery, Dr. Flores told the couple he was confident he had removed all the cancer he could see.

Her treatment wasn’t over. To eliminate any trace of disease, Dr. Flores created a plan with Kenneth Rosenzweig, MD, Chair of Radiation Oncology, for her to undergo 28 rounds of high-dose radiation to her chest cavity over a six-week period.

When the couple returned home to California in April 2013, she couldn’t move from one side of the couch to the other without feeling exhausted. But she slowly built up her strength, first walking around the block and doing breathing exercises to expand her remaining lung.

She measured her progress in small increments and stayed focused on her big goal, which was to become a mother.

Before chemotherapy, her eggs had been harvested and fertilized in a process called in vitro fertilization. She framed images of her frozen embryos and hung them on their bedroom wall. That future family was her biggest motivator.

Today, more than 13 years later, she is cancer-free. She and her husband are celebrating 16 years of marriage, and they are raising two daughters, Hope and Maggie, and an infant son, Brody.

She continues to receive regular scans and follow-up care from her health care team at Mount Sinai. “We do remote check-ins yearly,” she says. “I get scans out here and send Dr. Flores the results. He reviews them and then usually calls to give me his take, and to catch up.”

“Emily did her homework. She didn’t take ‘No’ for an answer when no other surgeon would touch her, and she displayed a drive and positive attitude that is needed to make it through the recovery,” Dr. Flores says. “I remember how young she was when she came to see me 13 years ago. She was a newlywed with dreams of starting a family.  Thankfully, we are seeing more and more long-term lung cancer survivors, stories of patients like Emily who are living significantly longer than in past decades due to major advances in early detection and advances in treatment options and surgery.”

Dr. Flores and Dr. Rosenzweig want to remind people that there is life after cancer.

“Celebrating long-term survivors like Emily and then seeing her beautiful family thrive is truly inspiring,” says Dr. Rosenzweig. “There is hope after lung cancer, there is a chance for long-term results.”

The U.S. five-year lung cancer survival rate has climbed to nearly 30 percent (up from just 18 percent less than a decade prior), according to the American Lung Association. Improvements in early detection with low-dose CT scans have played a significant role in these improved survival rates.

“Thankfully, we are seeing more and more long-term lung cancer survivors, stories of patients like Emily who are living significantly longer than in past decades due to major advances in early detection and advances in treatment options and surgery.” — Raja Flores, MD

As a non-smoker, Ms. Bennett Taylor’s diagnosis led her to ask questions about possible causes, like environmental exposure. She later learned that her home county in northern Idaho is identified as an area of concern for elevated radon levels. Her childhood home had a finished basement with bedrooms, including her own bedroom.

Radon is a naturally occurring radioactive gas that can accumulate inside homes and buildings. According to the U.S. Centers for Disease Control and Prevention, radon exposure causes an estimated 21,000 lung cancer deaths in the United States each year. It is the second-leading cause of lung cancer overall and a leading cause among people who have never smoked.

“I am fairly certain my lung cancer had something to do with my exposure to radon,” she says. Although her exposure cannot be confirmed as the cause of her cancer, her experience underscores that lung cancer can affect people who have never smoked.

Ms. Bennett Taylor works with GO2 for Lung Cancer, an organization that supported her throughout her journey. She raises awareness and connects directly with patients seeking guidance.

“If I had to go through everything I went through, it only makes sense that I pass along my knowledge and lessons learned to the next person, hoping to make their journey a little easier,” she says.

Her message to other patients is to become active participants in their care: educate yourself, ask questions, and speak up about your goals and concerns.

She encourages patients to seek reliable resources and work closely with their medical teams to explore their options. And she remains deeply grateful to Dr. Flores for believing in her when options seemed limited.

“His faith in me as a person, and not just a patient, gave me a shot at life,” she says.

A Routine Pre-Op Exam Uncovered a Silent Threat and Got One Beloved Professor Back to the Classroom

A photo of Karl Hoffman with his surgeon, John Phair, MD

Karl Hoffman with his surgeon, John Phair, MD

For more than 45 years, Karl Hoffman has dedicated his life to education.

A lifelong New Yorker who was raised in the Bronx and now calls Queens home, he has spent decades shaping young minds—from serving as a science department chair at a local high school to his current role teaching criminology at St. John’s University in Queens. At 77 years old, he’s still doing what he loves most: inspiring students in the classroom.

But earlier this year, while preparing for a knee replacement surgery to relieve years of debilitating arthritis pain, he learned that another, far more serious health issue demanded immediate attention.

He had no symptoms, and so he had no idea that one of the arteries supplying blood to his brain was nearly blocked.

“I felt perfectly fine,” he says. “I was focused on getting my knee replaced so I could get back to walking comfortably again. I never imagined they would find something that could have caused a stroke.”

As part of the routine pre-operative evaluation before his orthopedic surgery with Edward C. Yang, MD, he underwent a vascular examination. The screening revealed a 90 percent blockage in his carotid artery—a potentially life-threatening condition that significantly increases the risk of stroke.

The blockage was caught before it caused a stroke, and the vascular surgery team at Mount Sinai Queens acted quickly. Within weeks, he underwent transcarotid artery revascularization (TCAR), a unique and minimally invasive procedure designed to restore blood flow to the brain while reducing the risk of stroke.

“One of the biggest challenges with carotid artery disease is that many patients have no symptoms until they experience a stroke,” says John Phair, MD, Associate Professor of Vascular and Endovascular Surgery at the Icahn School of Medicine at Mount Sinai. “The routine pre-operative evaluation gave us the opportunity to detect the blockage early and treat it before it became a life-threatening emergency. TCAR allowed us to provide a less invasive treatment with a quicker recovery, helping him safely return to the life he enjoys.”

Mr. Hoffman underwent the procedure and was home the next day. Just one week later, he was back in the classroom.

“I couldn’t believe how quickly I recovered,” he says. “I was grateful to get back to my students and back to doing what I love.”

With the vascular procedure behind him, he went on to have his long-awaited knee replacement surgery. Once he recovers through physical therapy, he’s looking forward to returning to the activities arthritis had forced him to put on hold—from exploring museums and the New York Botanical Garden with his wife of 51 years to spending another semester in the classroom.

“Stories like Karl’s remind us why routine screenings are so important,” says Christopher Smolock, MD, Professor, Vascular Surgery and Radiology and Chief of Vascular Surgery, Mount Sinai Queens. “Advanced procedures like TCAR allow us to treat severe carotid artery disease before it leads to a stroke, and we’re proud to provide that level of specialized vascular care right here in Queens.”

For Mr. Hoffman, the surgical procedures mean he can focus on what comes next.

“You never know what a routine test might uncover,” he says. “I’m thankful the team found the blockage when they did. Because of them, I’m looking forward to getting back to my family, my students, and the life I love.”

At Mount Sinai Queens, patients have access to innovative vascular care close to home. From advanced diagnostic screenings to minimally invasive procedures like TCAR, our vascular surgery team is helping patients return to the lives they love with expert, compassionate care. To learn more or schedule a consultation with John Phair, MD, or Christopher Smolock, MD, contact Mount Sinai Queens Vascular Surgery at 718-808-7777 for Mount Sinai Doctors-Astoria and 718-520-6100 for Mount Sinai Doctors-Forest Hills.

What It’s Like to Participate in a Clinical Trial: One Cancer Patient Tells Her Story of Hope

A photo of Ellen Nissenbaum

“It has been a game changer,” says Ellen Nissenbaum. “Before the trial, I had seen a major decline in my health over four years.”

It’s that time again. In less than two hours, Ellen Nissenbaum must leave her office in Washington, D.C., where she works for a nonpartisan research and policy institute. She needs to catch the train to New York. There’s the usual rush to finish everything she needs to do and pack up the work she’ll bring with her on the train.

She’s not going for a weekend of visiting friends or touring the town. She’s going to see her cancer doctor and learn whether the clinical trial of a new medicine is continuing to keep her blood cancer in check, and she’s feeling the best she has felt in years.

“When I first started making this trip two years ago, it was harried and tense,” she says. “Now it’s become a routine—and one I actually look forward to doing.”

In fact, she’s excited to see her doctor, John O. Mascarenhas, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and the team at the Mount Sinai Tisch Cancer Center.

“I haven’t seen him in a while, and I look forward to learning about an upcoming change in my treatment,” she says.

If all goes as planned this time, she’ll only need to come to New York for her myeloproliferative neoplasm treatment once a month. That will make her life much easier.

Myeloproliferative neoplasms are a group of rare blood cancers where the bone marrow makes too many red blood cells, white blood cells, or platelets. About 20,000 new cases are diagnosed in the United States each year. Mount Sinai Tisch Cancer Center in New York is widely recognized as a global leader in the research and treatment of myeloproliferative neoplasms.

These blood cancers generally develop after age 50. They are chronic conditions that people can manage and live with for a long time if treated properly. However, some of these conditions can be more aggressive and develop into acute leukemia.

On the train

The train ride gives Ms. Nissenbaum a chance to settle in. It’s quiet, and she can work as the train speeds through Maryland, Delaware, and New Jersey toward Penn Station in New York. Then, she will spend the night in a hotel in Manhattan and take the subway to The Mount Sinai Hospital the next morning for her infusion therapy.

“I’ve made this trip so many times that I feel completely comfortable with it now,” she says.

She believes the clinical trial is literally making the difference between life and death.

“It has been a game changer. Before the trial, I had seen a major decline in my health over four years,” she says. “Now, because of this treatment, I have been fortunate that my cancer hasn’t made me sick or limited my life. I’m especially looking forward to seeing my test results tomorrow.”

A portrait of John Mascarenhas, MD..

“Ellen is a pioneer in cancer research,” says her doctor, John O. Mascarenhas, MD.

She often gets the lab results before the medical team does through her Mount Sinai MyChart app on her phone.

“I love seeing that. The infusion is keeping my platelets at normal levels. That’s something I hadn’t seen in 25 years,” she says.

Participation in the trial also helps cover her hotel, transportation, and meals. Without that support, she says participating would be extremely difficult for her—and impossible for many others.

Fortunately, her doctor referred her to Dr. Mascarenhas, who is an expert in myeloproliferative neoplasms. She had been with Mount Sinai for a few years when Dr. Mascarenhas presented the opportunity to her, and they made a decision to pursue this trial based on her disease features and her personal goals.

“The trial comes with costs in many ways, but those are nothing compared with what I’ve gained from being part of it and from being cared for by this incredible team,” she says.

Ms. Nissenbaum was the first person enrolled in the trial at Mount Sinai. She takes pride in knowing that the team has learned a great deal from her participation, and she hopes that knowledge will benefit others.

“I tease Dr. Mascarenhas that I’m his ‘guinea pig,’” she says.

“Ellen is a pioneer in cancer research as she was one of the very first patients in the world to receive a first-in-human immunotherapeutic for her myeloproliferative neoplasm,” says Dr. Mascarenhas. “She approached this trial and her disease with courage and a desire to be an active participant in the process. I admire her. We have been thrilled by the clinical response and the hope for disease modification in a chronic progressive hematologic malignancy.”

The next day

“Early Thursday morning, I wake up in New York City and head to Mount Sinai, where I’m warmly greeted by the nurses who have had my back for two and a half years,” she says.

“When I first started, I was terrified of needles, and infusions were traumatic,” she says. “The nurses listened, understood, and found ways to make the experience tolerable. Their compassion changed everything for me.”

She’s probably sat in every chair in the infusion center, and she even has a few favorites. About once a month, she brings the staff homemade chocolate-chip banana bread.

“It feels like such a small gesture for everything they do, but they seem to love it,” she says.

A photo of Ellen Nissenbaum in the hospital.

“When I first started, I was terrified of needles, and infusions were traumatic,” says Ms. Nissenbaum. “The nurses listened, understood, and found ways to make the experience tolerable. Their compassion changed everything for me.”

Heading home

After a half day at Tisch Cancer Center, she is ready to head home to Washington. These days, she’s excited about the possibility of coming less often while still being closely monitored remotely.

“It’s wonderful news—and another reminder of how fortunate I am to be on this trial and to have this remarkable team beside me,” she says.

Ellen Nissenbaum is part of a phase 1 (NCT05936359) open-label multicenter study with Incyte Corporation of INCA033989 administered as monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms with John O. Mascarenhas, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of Mount Sinai Tisch Cancer Center.

This Research Scientist Has Lived With MS for 20 Years. Here’s How He Has Remained Hopeful and Productive

A photo of Scott Mellis, MD, PhD, with one of the devices he has created, an apparatus that uses a swing arm to position binoculars or a small telescope in front of your eyes and hold them there hands-free.

Scott Mellis, MD, PhD, has lived with secondary progressive multiple sclerosis (MS) for more than 20 years under the care of doctors at The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai. It has not always been easy.

He has one message for anyone diagnosed with the chronic condition: “Be hopeful, recognize that you can have a good and productive life despite the MS.”

For him, that has meant a successful career as a medical researcher and, more recently, an active life in retirement dedicated to his lifelong passion for birdwatching and stargazing and committed to expanding opportunities for others like him living with MS or other disabilities. This includes a project to make it easier for others to obtain special equipment so they can continue to enjoy hobbies such as observing nature and the stars.

For much of his adult life, Dr. Mellis, had no serious health concerns. But he experienced a dramatic change after he slipped and fell during the winter of 2005, and a few months later his left-hand fingers “felt like they were moving through molasses” while playing the guitar.  A friend suggested he see a neurologist, and after an MRI, he was told he has MS.

“I was 51 years old when the diagnosis was made. A bit of a shock,” he recalls.

Soon after, he attended a Keystone Symposia on MS, a scientific conference that brings together researchers and clinicians to share advances in research and treatment. As a trained rheumatologist and immunologist whose medical career focused on treatments that could be helpful to people, he found the conference beneficial for understanding MS. Health care professionals he met there strongly recommended The Corinne Goldsmith Dickinson Center for Multiple Sclerosis. Aaron Miller, MD, the Center’s Medical Director, has been “my neurologist and counselor for 20 years,” he says.

“The sheer beauty of nature and birds, the awesomeness of celestial objects, provides a lot of comfort. People with MS have a lot of challenges, and a few moments of awe and wonder can really bring a lot of joy to one’s life.” — Scott Mellis, MD, PhD

How and when to disclose your MS to others is one of the first decisions people newly diagnosed have to encounter. Dr. Mellis kept his condition private for about a year. “I was fortunate to have a wonderfully supportive wife and family, and eventually I told my kids,” he says.

At Regeneron Pharmaceuticals in Tarrytown, New York, where Mellis headed the Department of Translational Medicine, he initially did not disclose his condition. But within a year “I became the guy riding around the office in the mobility scooter,” he recalls.

Colleagues were very supportive, and he was able to continue his leadership position researching and developing new drugs. Determined to not allow his progressive MS to hinder his career, he continued to work at Regeneron for another 15 years after his diagnosis.

Since retiring in early 2026, Dr. Mellis has pursued a mix of medically related work and his lifelong passions for birdwatching and stargazing. He was selected earlier this year to serve on the engagement coordination team of the International Progressive MS Alliance, a consortium of organizations from countries around the world that support MS research. In June, he traveled to Milan, Italy, for his first in-person meeting with the team, comprised of individuals who can share perspectives on living with MS and help advise the Alliance on deciding research priorities.

With his secondary progressive MS, he had to give up his favorite pastimes of cycling and playing tennis and squash.

“Once I developed MS, my new action sport became filling the bird feeder,” he says. “I liked to watch the birds at the feeder and started setting up binoculars to get a close-up view and try to take photographs of birds at the feeders.”

But he noticed that as his MS progressed, it became increasingly difficult to hold a pair of binoculars, or carry a tripod with a spotting scope that birders use, or set up a telescope to look at the stars.

Motivated to pursue his birdwatching and stargazing passions, he began to tinker at home with a parallelogram mount, an apparatus that uses a swing arm to position binoculars or a small telescope in front of your eyes and hold them there hands-free. “You can sit comfortably and enjoy a beautiful view of nature or the night sky,” he says.

Friends at the Audubon Society and the Westchester Amateur Astronomers club, two organizations he has long been active in were quick to help. For participants in the National MS Society’s Westchester Walk last May, the team set up six optic stations, a combination of binoculars and spotting scopes on parallelogram mounts as well as larger telescopes. “For people living with disability to be able to use these tools is really transformative” he says.

To share his knowledge and experience adapting equipment to appreciate nature, Dr. Mellis created an initiative called the Boundless Skies Alliance, and he is developing a website for people with MS or other disabilities to learn more about how to obtain and use readily available equipment to make these hobbies accessible. (Those seeking more information can contact him at sjmellis@gmail.com.)

“The sheer beauty of nature and birds, the awesomeness of celestial objects, provides a lot of comfort,” he says. “People with MS have a lot of challenges and a few moments of awe and wonder can really bring a lot of joy to one’s life.”

By Kenneth Bandler, a multiple sclerosis patient, advocate, and member of The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Advisory Board.

Stroke Patient Saved by Quick Clot Retrieval Using Minimally Invasive Procedure

A group portrait showing: Yohannes Melaku, MD, center, Critical Care Physician, is back to work after experiencing a stroke while visiting his patients in the Mount Sinai South Nassau Intensive Care Unit. He is joined by his neurologycare team, from left, Joseph Merims, RN, Interventional Radiology; Jonathan Sisti, MD, Cerebrovascular and Endovascular Neurosurgeon; M. Travis Caton, Jr., MD, Interventional Neuroradiologist; and Robert Croes, RN, Assistant Nurse Manager, Interventional Radiology.

Yohannes Melaku, MD, center, Critical Care Physician, is back to work after experiencing a stroke while visiting his patients in the Mount Sinai South Nassau Intensive Care Unit. He is joined by his neurology care team, from left, Joseph Merims, RN, Interventional Radiology; Jonathan Sisti, MD, Cerebrovascular and Endovascular Neurosurgeon; M. Travis Caton Jr., MD, Interventional Neuroradiologist; and Robert Croes, RN, Assistant Nurse Manager, Interventional Radiology.

One Friday last October began like any other for Yohannes Melaku, MD, 54. The Mount Sinai intensivist and nephrologist was visiting his patients in the hospital’s ICU when a sudden wave of nausea hit him. As he walked to the restroom, his left leg felt unusually heavy.

“My left leg was dragging like I was dragging a heavy rock,” he recalled. “While I was in the bathroom, the heaviness in my left leg got worse…I was shuffling. I thought it was something transient and that it would pass, but my leg felt heavier and heavier. Then I knew this must be serious.”

As he began feeling “cloudy,” he said he yanked on the emergency pull cord to call for help. ICU personnel pounded on the restroom door and then unlocked it to render aid to their colleague, rushing him to the Emergency Department.

A CT and MRI confirmed the diagnosis: a stroke in the right carotid artery caused by a blood clot. That day, Dr. Melaku had become one of the nearly 700,000 Americans to experience a stroke each year.

Within minutes, doctors rushed him to the hospital’s Radiology Department, where M. Travis Caton Jr., MD, Assistant Professor of Neurosurgery at the Icahn School of Medicine at Mount Sina and an interventional neuroradiologist, and Jonathan Sisti, MD, Assistant Professor of Neurosurgery and a cerebrovascular and endovascular neurosurgeon at the Mount Sinai Cerebrovascular Center, performed a thrombectomy. During the minimally invasive procedure, they guided a catheter equipped with a specialized tool through Dr. Melaku’s blood vessels to remove the clot and restore blood flow to his brain, reducing the risk of permanent tissue damage or death.

“He had a complete occlusion of his right internal carotid artery, which normally provides blood flow to 40-45 percent of the brain,” said Dr. Sisti. “Historically, that diagnosis—without thrombectomy—carries a mortality rate between 40-60 percent.”

After recovering from the stroke, Dr. Melaku is back in the ICU—this time, not as a patient, but as a medical provider with a new outlook on illness, patient care, and life.

“The time from the start of symptoms to intervention is extremely important,” he said. “As soon as the procedure was over, I regained all my function. I am 100 percent and have no residual weakness. If I had not gotten care in time, I would have been clinically disabled. It would have been disastrous.”

Alan Wong, DO, Chief Medical Officer and Senior Vice President of Medical Affairs at Mount Sinai South Nassau, echoed Dr. Melaku’s assessment.

“Behind every neurological diagnosis is a patient whose life has changed in an instant,” Dr. Wong said. “Expanding our services allows us to bring cutting-edge treatments and multidisciplinary expertise together to deliver the highest level of care.”

While Dr. Melaku’s medical training helped him to promptly recognize the seriousness of his symptoms, he said physicians can become desensitized to seeing illness through daily exposure and feel invulnerable.

“As physicians, we think of ourselves as invincible. Sickness is someone else’s problem,” he said. “It could happen to anyone—irrespective of your identity as a physician.”

The stroke also helped him to realize the importance of demonstrating compassion toward patients.

“The doctors followed up with me to see how I was,” he said. “I realized personally that the idea of connecting with patients means a lot.”

Since the stroke, Dr. Melaku is maintaining tighter control of his blood pressure. Besides that, he has taken his exercise routine up a notch, dropped a few pounds, and cut down on salt.

“I’m probably one of the luckiest persons in the world,” he said. “The doctors and nurses really impressed me. They are highly skilled and very caring…This experience helped me appreciate the power of modern medicine.”